MAbSilico is a premier TechBio company dedicated to developing and providing cutting-edge AI-based solutions for antibody drug design and discovery. They empower biotech and pharmaceutical companies to significantly leverage antibody discovery risks by providing high-potential computational candidates in just a matter of days. These candidates are meticulously designed and characterized in silico and subsequently validated with state-of-the-art biological technologies, ensuring a seamless transition from digital modeling to laboratory success. By combining sophisticated 3D modeling, complex interaction simulations, and advanced linear sequence analysis, MAbSilico defines antibody drug candidates through a rigorous assessment of their epitope, affinity, off-target risk, cross-species reactivity, and developability, ensuring they are fully prepared for biological activity evaluation.

Beyond their services, MAbSilico is advancing its own innovative discovery pipeline available for out-licensing, featuring high-quality leads in monoclonal, bispecific, and antibody-drug conjugate modalities. Their commitment to global innovation is reflected in an aggressive US development strategy, where they are actively seeking strategic partners to extend the deployment of their antibody design platform across the North American ecosystem. This international reach is further strengthened by their exclusive partnership with Yntoab to serve the Korean market and a landmark collaboration with Sartorius. The Sartorius partnership offers a comprehensive end-to-end solution that bridges the gap between lead candidate design and lead candidate production, including integrated cell line development to accelerate the path to clinical trials.

Furthermore, MAbSilico utilizes advanced NLP technologies to gather exhaustive information about antibodies and their targets from global databases, ensuring robust competitive landscape analysis and the freedom to operate for all computationally designed candidates. Through these integrated technologies and global alliances, MAbSilico transforms the traditional discovery process into a predictive, high-velocity engine for the next generation of immunotherapy.